# Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)

> **NCT04409509** · PHASE2 · COMPLETED · sponsor: **CSL Behring** · enrollment: 124 (actual)

## Conditions studied

- Coronavirus Disease 2019 (COVID-19)

## Interventions

- **BIOLOGICAL:** Garadacimab, Factor XIIa Antagonist Monoclonal Antibody
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04409509
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-01
- **Primary completion:** 2021-01-12
- **Final completion:** 2021-01-12
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2022-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04409509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04409509, "Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04409509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*